AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30376537
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (LDK) at 2.5 μg·kg·min for 48 hours
Trial: 30471966
Drug: Conventional aquatic
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional aquatic therapy (50min)
Trial: 25459890
Drug: Isoallopregnanolone (ISO)
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoallopregnanolone (ISO) administered in combination with Allopregnanolone (AP)
Trial: 18633421
Drug: Maternal massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal massage therapy (standard care plus maternal massage performed four times a day on the face and limbs)
Trial: 18633421
Drug: Maternal massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal massage therapy
Trial: 11309871
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg intra-nasal midazolam
Trial: 11309871
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg intra-nasal midazolam
Trial: 11309871
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intra-nasal midazolam
Trial: 9361167
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (OM20)
Trial: 9361167
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg once daily (OM10)
Trial: 31060106
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL) I (without disability)
Trial: 29776750
Drug: Typhim Vi®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhim Vi® (first dose) and Vaxigrip® (second dose)
Trial: 7813723
Drug: Heparin injected
RxNorm normalized name: heparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin injected into a central venous line 5 minutes before infrarenal aortic clamping (Group I)
Trial: 7813723
Drug: Heparin injected
RxNorm normalized name: heparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin injected into the distal aneurysm immediately after infrarenal aortic clamping (Group II)
Trial: 7813723
Drug: Heparin injected
RxNorm normalized name: heparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin injected into a central venous line immediately after infrarenal aortic clamping (Group III)
Trial: 2676647
Drug: Salsalate 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate 1.5 g twice daily
Trial: 7752752
Drug: MMF 3
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3 g
Trial: 2132179
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg b.i.d. for 1 week followed by 40 mg b.i.d. for 3 weeks
Trial: 620898
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (15 mg)
Trial: 9462188
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhaled nitric oxide)
Trial: 7875151
Drug: Ganciclovir plus
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir plus GM‐CSF (1‐8 micrograms/kg daily subcutaneously)
Trial: 26847114
Drug: Intravenous esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esmolol for 24 hours
Trial: 23084565
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (150 μg) followed by 300 IU rFSH in a GnRH antagonist protocol
Trial: 23084565
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol for poor responders (short agonist-hMG)
Trial: 18371596
Drug: Soda water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soda water (100 mL)
Trial: 30081337
Drug: School-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based drug prevention program #Tamojunto
Trial: 22292487
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T)
Trial: 22292487
Drug: Tobramycin ophthalmic
RxNorm normalized name: tobramycin ophthalmic
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin ophthalmic solution 0.3%
Trial: 22893628
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg intravenously every 4 weeks
Trial: 8299330
Drug: 4 pints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 pints of Dioralyte (glucose and electrolyte solution)
Trial: 27806647
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg slow-release L-cysteine
Trial: 21453351
Drug: α-blockers (tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-blockers (tamsulosin or alfuzosin)
Trial: 19148579
Drug: Intensified MAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified MAID (5 cycles, doses 20-33% higher per cycle)
Trial: 19148579
Drug: MAID (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAID (6 cycles: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine)
Trial: 17525497
Drug: Medicinal ointments
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicinal ointments based on Georgian mineral waters (N1 - 'Achtala'; N2 - 'Sairme'; N3 - 'Tschaltubo'; N4 - 'Amagleba')
Trial: 17525497
Drug: Medicinal ointments
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicinal ointments based on Georgian mineral waters
Trial: 9505879
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily (excluding those who died within 30 days)
Trial: 9505879
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (excluding those who died within 30 days)
Trial: 8496858
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg/day)
Trial: 31885287
Drug: Computer-based multidomain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based multidomain cognitive training program (RehaCom software), 15 weeks, twice a week, 1 hour per session
Trial: 8796406
Drug: Inhalational nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational nitric oxide (NO) therapy, mean concentration 4.9 +/- 0.8 ppm
Trial: 1732342
Drug: 1.25 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg/day cyclosporine
Trial: 1732342
Drug: 2.5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day cyclosporine
Trial: 6433737
Drug: Neuroleptic technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic technique (NLA) using fentanyl 0.0025 mg/kg and droperidol 0.125 mg/kg (Thalamonal)
Trial: 23962543
Drug: H‐HOPE intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H‐HOPE intervention (twice‐daily infant stimulation using ATVV and four maternal participatory guidance sessions plus two telephone calls)
Trial: 21959024
Drug: Standard guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guidelines treatment
Trial: 18460288
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gadolinium enhancement, perfusion, and cine imaging
Trial: 16847470
Drug: semisynthetic homoharringtonine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semisynthetic homoharringtonine (ssHHT) at a dose of 5 mg m(‐2) day(‐1) for 9 days
Trial: 7747718
Drug: 14-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day infusion of 30 mg/m2 of carboplatin (CBDCA) daily (Group A)
Trial: 7747718
Drug: 21-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-day infusion of carboplatin (CBDCA) beginning from the first day of radiotherapy (Group B)
Trial: 7747718
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received conventional radiotherapy (RT) with total doses ranging from 65 to 70 Gy
Trial: 28424260
Drug: Low-phytate maize
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-phytate maize (LP; 1.6 mg/g)
Trial: 28424260
Drug: Control maize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control maize (C; 7.1 mg/g)
Trial: 25918111
Drug: [(11)C]ORM‐13070 during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(11)C]ORM‐13070 during ketamine infusion
Trial: 23496375
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment alone
Trial: 15306704
Drug: Artesunate 4
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 4 mg/kg followed by mefloquine 15 mg/kg simultaneously (group A)
Trial: 11428736
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic solution twice daily adjunctive to loratadine 10 mg once daily
Trial: 9600500
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal corticosteroids
Trial: 1773908
Drug: Dimethindene maleate
RxNorm normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene maleate 3 mg
Trial: 31603205
Drug: SQ-LNSs until
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNSs until 6 mo postpartum, and SQ-LNSs for offspring (6 mg Fe/d) from 6 to 18 mo of age
Trial: 31603205
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplements until 6 mo postpartum
Trial: 1874201
Drug: Stimulation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation of ear and paravertebral points with small doses of fentanyl (mean 1.2 micrograms kg‐1)
Trial: 1874201
Drug: Moderate-dose fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose fentanyl (mean 22.9 micrograms kg‐1)
Trial: 6863224
Drug: amoxapine (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxapine (260 mg daily for 4 weeks)
Trial: 6863224
Drug: doxepin (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxepin (130 mg daily for 4 weeks)
Trial: 26915823
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure (300 μg PM2.5/m(3) for 120 min)
Trial: 7821201
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment with tissue-damaging procedures (epinephrine + polidocanol +/- NaCl in 26%, epinephrine + thermocoagulation in 7%)
Trial: 7821201
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment after recurrent bleeding
Trial: 7821201
Drug: Haemoglobin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin < 8 g/dl on admission
Trial: 23649554
Drug: rhPTH(1-84) 100
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH(1-84) 100 µg/d
Trial: 21353211
Drug: Ultrasound-guided lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided lidocaine injection (group U/S)
Trial: 19691829
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of ciprofloxacin or 7 days of empirical beta-lactams +/− gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded ciprofloxacin
Trial: 11275030
Drug: Ginger 1
RxNorm normalized name: GINGER 1 g in 100 TOPICAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger 1 g per day for 4 days
Trial: 9385881
Drug: Medications used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications used in heart failure
Trial: 8231601
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Mycobacterium w
Trial: 31625136
Drug: Immunosuppressive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drugs used to treat autoimmune conditions
Trial: 26915374
Drug: Sacubitril/valsartan 97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 97/103 mg twice daily
Trial: 11912261
Drug: AMG 073
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 073 (50 mg for 8 days)
Trial: 11912261
Drug: AMG 073
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 073 (any dose)
Trial: 10090643
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion (100 g of an amino acid mixture without tryptophan)
Trial: 2347954
Drug: Dilevalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (100 mg)
Trial: 18837970
Drug: Soy drink
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy drink enriched with 2.6 g plant sterol esters (1.6 g/d free plant sterol equivalents)
Trial: 9189212
Drug: Isoniazid 300
RxNorm normalized name: isoniazid 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg daily for 6 months
Trial: 12624612
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg plus Benazepril 10 mg o.d.
Trial: 8229544
Drug: Dioctahedral smectite
RxNorm normalized name: Dioctahedral smectite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctahedral smectite (DS) 1.5 g freshly dissolved in 50 ml of water, four times daily for 3 days
Trial: 16160875
Drug: Alcohol (1
RxNorm normalized name: POLYVINYL ALCOHOL (18000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1 ml/kg)
Trial: 31969238
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 0.5% podophyllotoxin solution and liquid nitrogen cryotherapy
Trial: 16445830
Drug: ML-DS children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-DS children vs. non-DS children in trials
Trial: 16445830
Drug: ML-DS children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-DS children
Trial: 12934465
Drug: Disease-modifying antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying antirheumatic drugs (DMARDs) including cyclosporin A and leflunomid
Trial: 12934465
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with 2 or 3 DMARDs
Trial: 12934465
Drug: Glucocorticosteroids (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroids (both small daily doses and pulse therapy)
Trial: 12934465
Drug: Biological agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological agents (monoclonal antibodies to TNF alpha and IL-4 or their receptor antagonists)
Trial: 12934465
Drug: Monitoring methods
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring methods for treatment safety
Trial: 10868713
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide via Respimat (RMT) 10 microg per puff, total dose 160 microg
Trial: 10868713
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide via Respimat (RMT) 20 microg per puff, total dose 320 microg
Trial: 10868713
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide via MDI (20 microg per puff, total dose 320 microg)
Trial: 20456515
Drug: bleaching gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching gel + halogen light (group 1)
Trial: 1799466
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b alone or in combination with chemotherapy
Trial: 1799466
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon
Trial: 1799466
Drug: Interferon plus
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon plus low-dose hydroxyurea
Trial: 6849533
Drug: SPP (Sus-Phrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP (Sus-Phrine followed by 2 placebo injections)
Trial: 19739698
Drug: Less frequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less frequent dispensing of buprenorphine/naloxone (thrice weekly)
Trial: 14687691
Drug: Immucytal (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immucytal (one tablet daily in the morning for 8 days per month for three consecutive months)
Trial: 14687691
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet daily in the morning for 8 days per month for three consecutive months)
Trial: 9070549
Drug: saruplase (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saruplase (80 mg/hour, n = 236)
Trial: 9070549
Drug: alteplase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alteplase (100 mg every 3 hours, n = 237)
Trial: 1598788
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 x 10(9) live bacteria
Trial: 1598788
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses every other day of 2 x 10(9) live bacteria
Trial: 8438616
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of 2 x 10(9) live bacteria after 6 months
Trial: 3025928
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (a competitive opiate receptor antagonist)
Trial: 26637080
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative feeding (oral clear fluids began up to six hours after surgery followed by solid foods as tolerated)
Trial: 23239679
Drug: Chicken noodle
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken noodle soup (355 ml)
Trial: 23239679
Drug: Water (355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (355 ml)
Trial: 12921494
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray 5mg
Trial: 12585821
Drug: computer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computer treatment
Trial: 28591387
Drug: Sublingual atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual atropine sulfate
Trial: 24932624
Drug: Corticosteroid spray
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid spray
Trial: 23557500
Drug: Preservative-free 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free 0.9% sodium chloride solution
Trial: 19674282
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Trial: 19674282
Drug: mean on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mean on-treatment ribavirin dose >13 mg/kg/day
Trial: 19674282
Drug: baseline factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baseline factors (serum HCV RNA <= 400,000 IU/mL, alanine aminotransferase >3 x ULN, non-cirrhotic status, age <= 40 years, white non-Latino ethnicity, body mass index <= 27 kg/m(2))